Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum: Alzheimer's disease brain-derived tau extracts show differential processing and transcriptional effects in human astrocytes.

iScience·2026

Same author

Proteomic analysis links truncated tau to lysosome motility, autophagy, and endo-lysosomal dysfunction.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultation.

Alzheimer's research & therapy·2025

Same author

Alzheimer's disease brain-derived tau extracts show differential processing and transcriptional effects in human astrocytes.

iScience·2025

Same author

Truncated tau disrupts autophagy and endolysosomal systems.

Autophagy reports·2025

Same author

Microbiota and cognitive impairment: Current challenges and future perspectives.

Journal of Alzheimer's disease : JAD·2024

Search research articles

Related Experiment Video

Updated: May 28, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Advances in tau-based drug discovery.

Wendy Noble¹, Amy M Pooler, Diane P Hanger

¹MRC Centre for Neurodegeneration Research, Department of Neuroscience (P037), King's College London, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF, UK. Tel: +44 20 7848 0578. wendy.noble@kcl.ac.uk.

Expert Opinion on Drug Discovery

|October 18, 2011

Summary

Tauopathies, like Alzheimer's disease, are linked to tau protein buildup. New therapies targeting tau pathways show promise for treating these neurodegenerative diseases.

More Related Videos

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Related Experiment Videos

Last Updated: May 28, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Area of Science:

Neuroscience
Pharmacology

Background:

Tauopathies, including Alzheimer's disease, are neurodegenerative disorders characterized by pathological tau protein lesions.
There is a critical need for disease-modifying therapies for tauopathies.

Purpose of the Study:

To review recent genetic and pharmacological approaches for reducing tau-mediated neurodegeneration.
To summarize evidence for targeting tau pathways in drug development.

Main Methods:

Review of recently published papers on tau-targeting therapies.
Summary of genetic and pharmacological strategies.

Main Results:

Identified approaches include preventing abnormal tau processing, increasing tau clearance, immune system therapies, and manipulating tau pre-mRNA.
Several small molecule tau-based treatments are in clinical trials.

Conclusions:

Therapies targeting tau are a promising basis for effective treatments for Alzheimer's disease and related tauopathies.
Outcomes of ongoing clinical trials are highly anticipated.